Cellular Trafficking of Sn-2 Phosphatidylcholine Prodrugs Studied with Fluorescence Lifetime Imaging and Super-resolution Microscopy
-
Published:2018-06-30
Issue:2
Volume:1
Page:128-145
-
ISSN:2639-9431
-
Container-title:Precision Nanomedicine
-
language:en
-
Short-container-title:PRNANO
Author:
Maji Dolonchampa1ORCID, Lu Jin2ORCID, Sarder Pinaki3ORCID, Schmieder Anne H4, Cui Grace4, Yang Xiaoxia4, Pan Dipanjan5ORCID, Achilefu Samuel6ORCID, Lanza Gregory M4
Affiliation:
1. Optical Radiology Lab, Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA 2. Department of Electrical and Systems Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA 3. Department of Pathology and Anatomical Sciences, Jacobs School of Medicine & Biomedical Sciences, University of Buffalo, Buffalo, NY 14203 4. Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA 5. Department of Bioengineering, University of Illinois at Urbana-Champaign, Champaign, IL, USA 6. Department of Biomedical Engineering, Washington University in St. Louis, MO 63130, USA
Abstract
While the in vivoefficacy of Sn-2 phosphatidylcholine prodrugs incorporated into targeted, non-pegylated lipid-encapsulated nanoparticles was demonstrated in prior preclinical studies, the microscopic details of cell prodrug internalization and trafficking events are unknown. Classic fluorescence microscopy, fluorescence lifetime imaging microscopy, and single-molecule super-resolution microscopy were used to investigate the cellular handling of doxorubicin-prodrug and AlexaFluor-488-prodrug. Sn-2 phosphatidylcholine prodrugs delivered by hemifusion of nanoparticle and cell phospholipid membranes functioned as phosphatidylcholine mimics, circumventing the challenges of endosome sequestration and release. Phosphatidylcholine prodrugs in the outer cell membrane leaflet translocated to the inner membrane leaflet by ATP-dependent and ATP-independent mechanisms and distributed broadly within the cytosolic membranes over the next 12 h. A portion of the phosphatidylcholine prodrug populated vesicle membranes trafficked to the perinuclear Golgi/ER region, where the drug was enzymatically liberated and activated. Native doxorubicin entered the cells, passed rapidly to the nucleus, and bound to dsDNA, whereas DOX was first enzymatically liberated from DOX-prodrug within the cytosol,particularly in the perinuclear region, before binding nuclear dsDNA. Much of DOX-prodrug was initially retained within intracellular membranes. In vitroanti-proliferation effectiveness of the two drug delivery approaches was equivalent at 48 h, suggesting that residual intracellular DOX-prodrug may constitute a slow-release drug reservoir that enhances effectiveness. We have demonstrated thatSn-2 phosphatidylcholine prodrugs function as phosphatidylcholine mimics following reported pathways of phosphatidylcholine distribution and metabolism. Drug complexed to the Sn-2 fatty acid is enzymatically liberated and reactivated over many hours, which may enhance efficacy over time.
Funder
Foundation for Barnes-Jewish Hospital Office of Extramural Research, National Institutes of Health
Publisher
Andover House Inc
Reference45 articles.
1. [1] G. M. Lanza, C. Moonen, J. R. Baker, Jr., E. Chang, Z. Cheng, P. Grodzinski, K. Ferrara, K. Hynynen, G. Kelloff, Y. E. Lee, A. K. Patri, D. Sept, J. E. Schnitzer, B. J. Wood, M. Zhang, G. Zheng, and K. Farahani, “Assessing the barriers to image-guided drug delivery,” Wiley Interdiscip Rev Nanomed Nanobiotechnol, vol. 6, no. 1, pp. 1-14, Jan-Feb, 2014. 2. [2] G. M. Lanza, X. Yu, P. M. Winter, D. R. Abendschein, K. K. Karukstis, M. J. Scott, L. K. Chinen, R. W. Fuhrhop, D. E. Scherrer, and S. A. Wickline, “Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis,” Circulation, vol. 106, no. 22, pp. 2842-7, Nov 26, 2002. 3. [3] P. M. Winter, A. M. Neubauer, S. D. Caruthers, T. D. Harris, J. D. Robertson, T. A. Williams, A. H. Schmieder, G. Hu, J. S. Allen, E. K. Lacy, H. Zhang, S. A. Wickline, and G. M. Lanza, “Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis,” Arterioscler Thromb Vasc Biol, vol. 26, no. 9, pp. 2103-9, Sep, 2006. 4. [4] K. C. Partlow, G. M. Lanza, and S. A. Wickline, “Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery,” Biomaterials, vol. 29, no. 23, pp. 3367-75, Aug, 2008. 5. [5] T. Cyrus, H. Zhang, J. S. Allen, T. A. Williams, G. Hu, S. D. Caruthers, S. A. Wickline, and G. M. Lanza, “Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury,” Arterioscler Thromb Vasc Biol, vol. 28, no. 5, pp. 820-6, May, 2008.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|